Trastuzumab-induced cardiotoxicity in early breast cancer over a 10-year period in Uruguay.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
29 Jul 2022
29 Jul 2022
Historique:
entrez:
29
7
2022
pubmed:
30
7
2022
medline:
3
8
2022
Statut:
epublish
Résumé
This srudy aimed to estimate the prevalence of trastuzumab-induced cardiotoxicity in Uruguayan women diagnosed with human epidermal growth factor receptor 2 (HER2)-positive breast cancer over a 10-year period, who were treated under the financial coverage of the National Resources Fund (Fondo Nacional de Recursos). This was an observational, descriptive study based on the analysis of an anonymized database of Uruguayan women diagnosed with HER2-positive breast cancer who received adjuvant trastuzumab treatment from to 2006 to 2016, provided by the Fondo Nacional de Recursos. Statistical analysis was performed using SPSS Statistics version 25, and variables were assessed using measures of central tendency, dispersion, contingency tables, and proportions. The chi-square test was used to analyze the association between the different variables. The study included 1401 patients diagnosed with stage I to III HER2-positive breast cancer. The mean age at diagnosis was 52 years. The prevalence of cardiotoxicity was 20.3%. Most patients who discontinued treatment owing to cardiotoxicity eventually resumed treatment (92.6%). Moreover, the prevalence of cardiotoxicity was similar among patients who received regimens with and without anthracyclines. No association was observed between prior cardiovascular events or trastuzumab administration (concurrent vs sequential) and the development of cardiotoxicity. In the present study, the prevalence of cardiotoxicity was similar to that reported nationally and internationally. Most patients did not develop cardiotoxicity, while the ones who developed it remained asymptomatic and cardiotoxicity was reversible.
Identifiants
pubmed: 35905268
doi: 10.1097/MD.0000000000029927
pii: 00005792-202207290-00071
pmc: PMC9333491
doi:
Substances chimiques
Anthracyclines
0
Receptor, ErbB-2
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29927Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding and conflicts of interest to disclose.
Références
Br Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
Comision Honoraria de Lucha contra el Cancer. Annual report. Period 2012-2016. Available at: https://www.comisioncancer.org.uy/Ocultas/RESUMENES-ESTADISTICOS-Periodo-2012-2016-uc264 [access date January 10, 2021].
Baselga J, Perez EA, Pienkowski T, et al. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist. 2006;11(suppl 1):4–12.
Barrios E, Garau M. Cáncer: magnitud del problema en el mundo y en Uruguay, aspectos epidemiológicos. Anfamed. 2017;4:04–66.
Conzen SD, Grushko TA, Olopade OI. Cancer of the breast. DeVita VT, Lawrence TS, Rosenberg S, eds. In: DeVita, Hellman & Rosenberg’s Cancer: Principles & Practices of Oncology. 8th ed. Philadelphia, PA: Lippincott, Williams & Wilkins, 2008:1595–1605.
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.
Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389:1195–205.
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273–83.
Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 3366;2011:3373.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72.
Uruguayan National Resource Fund Available at: http://www.fnr.gub.uy/sites/default/files/normativas/medicamentos/n_trat_canmama.pdf [access date October 6, 2020].
Camejo N, Castillo C, Alonso R, et al. Effectiveness of trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in a real-life setting: one decade of experience under national treatment coverage regulations. JCO Glob Oncol. 2020;6:217–23.
Jones RL, Smith IE. Efficacy and safety of trastuzumab. Expert Opin Drug Saf. 2004;3:317–27.
Sardesai S, Sukumar J, Kassem M, et al. Clinical impact of interruption in adjuvant trastuzumab therapy in patients with operable HER-2 positive breast cancer. Cardiooncology. 2020;6:26.
Perez E, Morgan J. Cardiotoxicity of trastuzumab and other HER2-targeted agents. Available at: http://www.uptodate.com/contents/cardiotoxicity-of-trastuzumab-and-other-her2-targeted-agents [access date January 18 2020].
Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin. 2016;66:309–25.
Yu AF, Yadav NU, Lung BY, et al. Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. Breast Cancer Res Treat. 2015;149:489–95.
Gómez A, Américo C, Janssen B, et al. Cardiotoxicidad por trastuzumab en pacientes con cáncer de mama. Serie de casos. Rev Urug Cardiol. 2019; 34: 36–43.
Camejo N, Schiavone A, Díaz M, et al. Cardiotoxicidad inducida por trastuzumab en pacientes uruguayas portadoras de cáncer de mama HER positivo. Arch. Med Int. 2015; 37: 109–113.
Anderson WF, Chu KC, Chatterjee N, et al. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J Clin Oncol. 2001;19:18–27.
Tocchetti CG, Ragone G, Coppola C, et al. Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. Eur J Heart Fail. 2012;14:130–7.
Yasui Y, Potter JD. The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control. 1999;10:431–7.